Syncona H1 2026 presentation: Beacon drives NAV gain, M&A tailwinds build
Syncona Ltd reported a 3.0% NAV increase for H1 2026, driven by Beacon Therapeutics' clinical data and M&A tailwinds. 92% of its £921M portfolio is in clinical-stage or commercial companies, with a 39.9% share price gain. Portfolio companies attracted £220M in investments, and Syncona expects further value inflection points.


